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Reduced oxygen availability plays a crucial role in malignancy of solid tumors, 
including breast cancer. Even if the presence of hypoxic areas is common in all breast 
lesions, no data clearly correlate low oxygenation with the acquisition of malignant 
features by non-invasive cells, particularly by cells from ductal carcinoma in situ 
(DCIS), the most frequently diagnosed tumor in women in industrialized countries 
[1]. We demonstrated that 96 hours of culture under moderate hypoxia is sufficient to 
induce in DCIS-derived cells motility and epithelial-to-mesenchymal transition (EMT) 
and to enlarge the number of cells expressing the stem cell marker CD133, indicative 
of their increased malignant potential. 
Administration of all-trans retinoic acid (ATRA), a well-known anti-leukemic 
drug with an anti-tumor role in invasive breast tumor cells [2], supports the epithelial 
phenotype of DCIS-derived cells cultured under hypoxia and reduces the number of 
CD133 positive cells, abrogating almost completely the effects of poor oxygenation. 
In DCIS-derived cells, as in leukemic cells, ATRA up-regulates the β2 isoform of PI-
PLC (PLC-β2), ectopically expressed in invasive breast tumors in which counter-
acts the effects of hypoxia on both EMT and CD133 levels [3]. This suggests that the 
mechanisms triggered by ATRA in non-invasive breast tumor cells cultured under 
hypoxia may, at least in part, depend on PLC-β2 activity.
Overall, we assigned to hypoxia a role in increasing the malignant potential of 
DCIS-derived cells and identified in ATRA, currently used in treating acute promye-
locytic leukemia (APL), an agonist potentially useful in preventing malignant pro-
gression of non-invasive breast lesions with hypoxic areas.
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